2006;40(suppl 1):S5–S10.

60. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and

nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver

biopsy: a prospective study. Gastroenterology 2011;140:124–131.

61. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic

approaches. J Gastroenterol Hepatol 2013;28 (suppl 1):68–76.

62. Browning JD, Kumar KS, Saboorian MH, et al. Ethnic differences in the prevalence of cryptogenic

cirrhosis. Am J Gastroenterol 2004;99:292–298.

63. Takamatsu S, Noguchi N, Kudoh A, et al. Influence of risk factors for metabolic syndrome and nonalcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma.

Hepatogastroenterology 2008;55:609–614.

64. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer

in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625–1638.

65. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis

severity in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1961–1971.

66. Friedman SL. Liver fibrosis in 2012: convergent pathways that cause hepatic fibrosis in NASH. Nat

Rev Gastroenterol Hepatol 2013;10:71–72.

67. Ma YY, Li L, Yu CH, et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.

World J Gastroenterol 2013;19:6911–6918.

68. McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am 2014;98:39–54.

69. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for

treatment of hepatitis C infection. N Engl J Med 2009;361:580–593.

70. Chou R, Hartung D, Rahman B, et al. Comparative effectiveness of antiviral treatment for hepatitis

C virus infection in adults: a systematic review. Ann Intern Med 2013;158:114–123.

71. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously

treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–221.

72. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C

virus genotype 1. N Engl J Med 2014;370:222–232.

73. Shindo M, Ken A, Okuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients

with chronic hepatitis C responding differently to interferon therapy. Cancer 1999;85:1943–1950.

74. Szakacs JG, Szakacs JE. Progress in diagnosis of hepatitis and the cirrhotic liver. Ann Clin Lab Sci

1999;29:87–103.

75. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37(suppl 2):S88–

S94.

76. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996;335:1570–1580.

77. Portmann B, Popper H, Neuberger J, et al. Sequential and diagnostic features in primary biliary

cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985;88:1777–1790.

78. Bhandari BM, Bayat H, Rothstein KD. Primary biliary cirrhosis. Gastroenterol Clin North Am

2011;40:373–386, viii.

79. Balasubramaniam K, Grambsch PM, Wiesner RH, et al. Diminished survival in asymptomatic

primary biliary cirrhosis. A prospective study. Gastroenterology 1990;98:1567–1571.

80. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of

symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994;20:707–713.

81. Al-Harthy N, Kumagi T. Natural history and management of primary biliary cirrhosis. Hepat Med

2012;4:61–71.

82. Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in

primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992;16:1290–1299.

83. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325–332.

84. Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing

cholangitis. J Hepatol 2000;32:182–187.

85. Liu JZ, Hov JR, Folseraas T, et al. Dense genotyping of immune-related disease regions identifies

nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013;45:670–675.

86. Zein CO. Primary sclerosing cholangitis. Clin Liver Dis 2013;17:211–227.

1535

87. Bergquist A, Glaumann H, Persson B, et al. Risk factors and clinical presentation of hepatobiliary

carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology

1998;27:311–316.

88. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing

cholangitis. J Hepatol 2002;36:321–327.

89. Barr Fritcher EG, Caudill JL, Blue JE, et al. Identification of malignant cytologic criteria in

pancreatobiliary brushings with corresponding positive fluorescence in situ hybridization results.

Am J Clin Pathol 2011;136:442–449.

90. Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and

advances in diagnosis and management. Gastroenterology 2013;145:521–536.

91. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis.

Hepatology 2010;51:660–678.

92. De V I, Steers JL, Burch PA, et al. Prolonged disease-free survival after orthotopic liver

transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000;6:309–

316.

93. Stal P, Broome U, Scheynius A, et al. Kupffer cell iron overload induces intercellular adhesion

molecule-1 expression on hepatocytes in genetic hemochromatosis. Hepatology 1995;21:1308–1316.

94. Wheeler CJ, Kowdley KV. Hereditary hemochromatosis: a review of the genetics, mechanism,

diagnosis, and treatment of iron overload. Compr Ther 2006;32:10–16.

95. Schilsky ML. Wilson’s disease. In: Schiff ER, Sorrell M, Maddrey WC, eds. Diseases of the Liver.

Philadelphia, PA: JB Lippincott; 1999:1091–1106.

96. Safran AP, Schaffner F. Chronic passive congestion of the liver in man. Electron microscopic study

of cell atrophy and intralobular fibrosis. Am J Pathol 1967;50:447–463.

97. Dunn GD, Hayes P, Breen KJ, et al. The liver in congestive heart failure: a review. Am J Med Sci

1973;265:174–189.

98. Rosenberg P. The liver in circulatory failure. In: Schiff ER, Sorrell M, Maddrey WC, eds. Diseases of

the Liver. Philadelphia, PA: JB Lippincott; 1999:1215–1227.

99. Tilanus HW. Budd–Chiari syndrome. Br J Surg 1995;82:1023–1030.

100. Gupta S, Barter S, Phillips GW, et al. Comparison of ultrasonography, computed tomography and

99mTc liver scan in diagnosis of Budd-Chiari syndrome. Gut 1987;28:242–247.

101. Ferral H, Behrens G, Lopera J. Budd-Chiari syndrome. AJR Am J Roentgenol 2012;199:737–745.

102. Zhang Y, Zhang XM, Prowda JC, et al. Changes in hepatic venous morphology with cirrhosis on

MRI. J Magn Reson Imaging 2009;29:1085–1092.

103. Ishikawa T, Ichida T, Matsuda Y, et al. Reduced expression of thrombopoietin is involved in

thrombocytopenia in human and rat liver cirrhosis. J Gastroenterol Hepatol 1998;13:907–913.

104. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009;49:1017–1044.

105. Simonovsky V. The diagnosis of cirrhosis by high resolution ultrasound of the liver surface. Br J

Radiol 1999;72:29–34.

106. Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal

hypertension. World J Gastroenterol 2014;20:4300–4315.

107. Holmberg SD, Lu M, Rupp LB, et al. Noninvasive serum fibrosis markers for screening and staging

chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2013;57:240–246.

108. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that

identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846–854.

109. Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver

disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med

2011;43:617–649.

110. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with

hepatitis C virus infection: a prospective study. Lancet 2001;357:1069–1075.

111. Ohsuga M, Moreau R, Hartleb M, et al. Blunted systemic, splanchnic, and renal hemodynamic

responses to atrial natriuretic peptide in rats with cirrhosis. J Hepatol 1994;20:91–96.

112. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with

cirrhosis. J Hepatol 2008;48(suppl 1):S93–S103.

1536

113. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal

syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229–236.

114. Martin-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with

cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352–1359.

115. Sharma P, Kumar A, Shrama BC, et al. An open label, pilot, randomized controlled trial of

noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of

response. Am J Gastroenterol 2008;103:1689–1697.

116. Oliver JA, Verna EC. Afferent mechanisms of sodium retention in cirrhosis and hepatorenal

syndrome. Kidney Int 2010;77:669–680.

117. Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver: its relation of portal

hypertension, ascites, and renal failure. J Clin Invest 1967;46:1297–1308.

118. Levy M. Sodium retention and ascites formation in dogs with experimental portal cirrhosis. Am J

Physiol 1977;233:F572–F585.

119. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for

the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–1157.

120. P G. Renal Complications. In: Schiff ER, Sorrell M, Maddrey WC, eds. Diseases of the Liver.

Philadelphia, PA: JB Lippincott; 1999:453–464.

121. Sarela AI, Mihaimeed FM, Batten JJ, et al. Hepatic and splanchnic nitric oxide activity in patients

with cirrhosis. Gut 1999;44:749–753.

122. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and

sodium and water retention in cirrhosis. N Engl J Med 1998;339:533–541.

123. Levy M, Allotey JB. Temporal relationships between urinary salt retention and altered systemic

hemodynamics in dogs with experimental cirrhosis. J Lab Clin Med 1978;92:560–569.

124. Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe

hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994;4:1522–1530.

125. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064–2077.

126. Montoliu S, Balleste B, Planas R, et al. Incidence and prognosis of different types of functional renal

failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol 2010;8:616–622.

127. Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol

Hepatol 2012;9:382–391.

128. Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on

vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576–584.

129. Singer JA, Kaplan MM, Katz RL. Cirrhotic pleural effusion in the absence of ascites. Gastroenterology

1977;73:575–577.

130. Fitz G. Systemic complications of liver disease. In: Feldman M, ed. Sleisenger and Fordtran’s

Gastrointestinal and Liver Disease. Philadelphia, PA: Saunders; 1998:1340–1342.

131. Berkowitz KA, Butensky MS, Smith RL. Pulmonary function changes after large volume

paracentesis. Am J Gastroenterol 1993;88:905–907.

132. Porcel JM. Management of refractory hepatic hydrothorax. Curr Opin Pulm Med 2014;20:352–357.

133. Hopkins WE, Waggoner AD, Barzilai B. Frequency and significance of intrapulmonary right-to-left

shunting in end-stage hepatic disease. Am J Cardiol 1992;70:516–519.

134. Hourani JM, Bellamy PE, Tashkin DP, et al. Pulmonary dysfunction in advanced liver disease:

frequent occurrence of an abnormal diffusing capacity. Am J Med 1991;90:693–700.

135. Rodriquez-Roisin R, Krowka MJ, Herve P, et al. Highlights of the ERS Task Force on pulmonaryhepatic vascular disorders (PHD). J Hepatol 2005;42:924–927.

136. Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD

exceptions for liver transplantation: a contemporary view and look forward. J Hepatol

2013;59:367–374.

137. McAdams HP, Erasmus J, Crockett R, et al. The hepatopulmonary syndrome: radiologic findings in

10 patients. AJR Am J Roentgenol 1996;166:1379–1385.

138. Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease.

Hepatology 2014;59:1627–1637.

139. Krowka MJ, Wiseman GA, Burnett OL, et al. Hepatopulmonary syndrome: a prospective study of

1537

relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake

after (99m)Tc MAA lung scanning. Chest 2000;118:615–624.

140. De Wolf AM, Begliomini B, Gasior TA, et al. Right ventricular function during orthotopic liver

transplantation. Anesth Analg 1993;76:562–568.

141. Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic

experience categorized by treatment subgroups. Am J Transplant 2008;8:2445–2453.

142. Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension.

Hepatology 2008;48:196–203.

143. Krowka MJ, Fallon MB, Mulligan DC, et al. Model for end-stage liver disease (MELD) exception for

portopulmonary hypertension. Liver Transpl 2006;12:S114–S116.

144. Nomura F, Ohnishi K, Terabayashi H, et al. Effect of intrahepatic portal-systemic shunting on

hepatic ammonia extraction in patients with cirrhosis. Hepatology 1994;20:1478–1481.

145. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver

disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991;11:337–341.

146. Schafer DF, Jones EA. Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter

system. Lancet 1982;1:18–20.

147. Mullen KD, Martin JV, Mendelson WB, et al. Could an endogenous benzodiazepine ligand

contribute to hepatic encephalopathy? Lancet 1988;1:457–459.

148. Bengtsson F, Gage FH, Jeppson B, et al. Brain monoamine metabolism and behavior in portacavalshunted rats. Exp Neurol 1985;90:21–35.

149. Zieve L, Doizaki WM, Zieve J. Synergism between mercaptans and ammonia or fatty acids in the

production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin

Med 1974;83:16–28.

150. Yurdaydin C, Karavelioglu D, Onaran O, et al. Opioid receptor ligands in human hepatic

encephalopathy. J Hepatol 1998;29:796–801.

151. Schenker S, Hoyumpa AM Jr. Pathophysiology of hepatic encephalopathy. Hosp Pract (Off Ed)

1984;19:99–103, 107–108, 110–114 passim.

152. Als-Nielsen B, Koretz RL, Kjaergard LL, et al. Branched-chain amino acids for hepatic

encephalopathy. Cochrane Database Syst Rev 2003;(2):CD001939.

153. Malaguarnera M, Vacante M, Motta M, et al. Acetyl-L-carnitine improves cognitive functions in

severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis

2011;26:281–289.

154. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment

of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology

1977;72:573–583.

155. Mortensen PB. The effect of oral-administered lactulose on colonic nitrogen metabolism and

excretion. Hepatology 1992;16:1350–1356.

156. Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose

and glucose. J Med Microbiol 1980;13:177–191.

157. Vince A, Zeegen R, Drinkwater JE, et al. The effect of lactulose on the faecal flora of patients with

hepatic encephalopathy. J Med Microbiol 1974;7:163–168.

158. Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut

1982;23:1–7.

159. Leise MD, Poterucha JJ, Kamath PS, et al. Management of hepatic encephalopathy in the hospital.

Mayo Clin Proc 2014;89:241–253.

160. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing

rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J

Gastroenterol 2013;108:1458–1463.

161. Reynolds TB, Balfour DC Jr, Levinson DC, et al. Comparison of wedged hepatic vein pressure with

portal vein pressure in human subjects with cirrhosis. J Clin Invest 1955;34:213–218.

162. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in

cirrhotic rats. Gastroenterology 1984;87:1120–1126.

163. Moller S, Christensen E, Henriksen JH. Continuous blood pressure monitoring in cirrhosis.

1538

Relations to splanchnic and systemic haemodynamics. J Hepatol 1997;27:284–294.

164. Battista S, Bar F, Mengozzi G, et al. Hyperdynamic circulation in patients with cirrhosis: direct

measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997;26:75–80.

165. Jaffe DL, Chung RT, Friedman LS. Management of portal hypertension and its complications. Med

Clin North Am 1996;80:1021–1034.

166. Gupta TK, Chen L, Groszmann RJ. Pathophysiology of portal hypertension. Baillieres Clin

Gastroenterol 1997;11:203–219.

167. Budd BG. On Diseases of the Liver. London: John Churchill; 1845.

168. Chiari H. Uber die selbstandige phlebitis obliterans der hauptstamme der venae hepaticae als

todesursache. Beitr Z Pathol Anat 1899;26:1–18.

169. Gordon SC, Polson DJ, Shirkhoda A. Budd-Chiari syndrome complicating pre-eclampsia: diagnosis

by magnetic resonance imaging. J Clin Gastroenterol 1991;13:460–462.

170. Valla D, Le MG, Poynard T, et al. Risk of hepatic vein thrombosis in relation to recent use of oral

contraceptives. A case-control study. Gastroenterology 1986;90:807–811.

171. Mitchell MC, Boitnott JK, Kaufman S, et al. Budd-Chiari syndrome: etiology, diagnosis and

management. Medicine (Baltimore) 1982;61:199–218.

172. Lin J, Chen XH, Zhou KR, et al. Budd-Chiari syndrome: diagnosis with three-dimensional contrastenhanced magnetic resonance angiography. World J Gastroenterol 2003;9:2317–2321.

173. Cameron JL, Maddrey WC. Mesoatrial shunt: a new treatment for the Budd-Chiari syndrome. Ann

Surg 1978;187:402–406.

174. Cameron JL, Herlong HF, Sanfey H, et al. The Budd-Chiari syndrome. Treatment by mesentericsystemic venous shunts. Ann Surg 1983;198:335–346.

175. Halff G, Todo S, Tzakis AG, et al. Liver transplantation for the Budd-Chiari syndrome. Ann Surg

1990;211:43–49.

176. Cura M, Haskal Z, Lopera J. Diagnostic and interventional radiology for Budd-Chiari syndrome.

Radiographics 2009;29:669–681.

177. Shaked A, Goldstein RM, Klintmalm GB, et al. Portosystemic shunt versus orthotopic liver

transplantation for the Budd-Chiari syndrome. Surg Gynecol Obstet 1992;174:453–459.

178. Rautou PE, Moucari R, Escolano S, et al. Prognostic indices for Budd-Chiari syndrome: valid for

clinical studies but insufficient for individual management. Am J Gastroenterol 2009;104:1140–1146.

179. Carnevale FC, Szejnfeld D, Moreira AM, et al. Long-term follow-up after successful transjugular

intrahepatic portosystemic shunt placement in a pediatric patient with Budd-Chiari syndrome.

Cardiovasc Intervent Radiol 2008;31:1244–1248.

180. Blum U, Rossle M, Haag K, et al. Budd-Chiari syndrome: technical, hemodynamic, and clinical

results of treatment with transjugular intrahepatic portosystemic shunt. Radiology 1995;197:805–

811.

181. Rossle M, Olschewski M, Siegerstetter V, et al. The Budd-Chiari syndrome: outcome after treatment

with the transjugular intrahepatic portosystemic shunt. Surgery 2004;135:394–403.

182. Orozco H, Takahashi T, Mercado MA, et al. Surgical management of extrahepatic portal

hypertension and variceal bleeding. World J Surg 1994;18:246–250.

183. Giouleme O, Theocharidou E. Management of portal hypertension in children with portal vein

thrombosis. J Pediatr Gastroenterol Nutr 2013;57:419–425.

184. Cohen J, Edelman RR, Chopra S. Portal vein thrombosis: a review. Am J Med 1992;92:173–182.

185. Parvey HR, Raval B, Sandler CM. Portal vein thrombosis: imaging findings. AJR Am J Roentgenol

1994;162:77–81.

186. de Ville de GJ, Alberti D, Falchetti D, et al. Treatment of extrahepatic portal hypertension in

children by mesenteric-to-left portal vein bypass: a new physiological procedure. Eur J Surg

1999;165:777–781.

187. Loftus JP, Nagorney DM, Ilstrup D, et al. Sinistral portal hypertension. Splenectomy or expectant

management. Ann Surg 1993;217:35–40.

188. Brown RS Jr, Kumar KS, Russo MW, et al. Model for end-stage liver disease and Child-TurcottePugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and

resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl

1539

2002;8:278–284.

189. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to

MELD. Mayo end-stage liver disease. Hepatology 2001;33:473–475.

190. Botta F, Giannini E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in

patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut

2003;52:134–139.

191. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing

prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002;2:2.

192. Carbo J, Garcia-Samaniego J, Castellano G, et al. Liver cirrhosis and mortality by abdominal

surgery. A study of risk factors. Rev Esp Enferm Dig 1998;90:105–112.

193. Mansour A, Watson W, Shayani V, et al. Abdominal operations in patients with cirrhosis: still a

major surgical challenge. Surgery 1997;122:730–735.

194. Noda T. Angioarchitectural study of esophageal varices. With special reference to variceal rupture.

Virchows Arch A Pathol Anat Histopathol 1984;404:381–392.

195. Kamath PS. Esophageal variceal bleeding: primary prophylaxis. Clin Gastroenterol Hepatol

2005;3:90–93.

196. Roberts LR, Kamath PS. Pathophysiology of variceal bleeding. Gastrointest Endosc Clin N Am

1999;9:167–174.

197. Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gastric varices:

a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992;16:1343–1349.

198. Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices

and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922–938.

199. Sanyal AJ, Fontana RJ, Di Bisceglie AM, et al. The prevalence and risk factors associated with

esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc

2006;64:855–864.

200. Cales P, Desmorat H, Vinel JP, et al. Incidence of large oesophageal varices in patients with

cirrhosis: application to prophylaxis of first bleeding. Gut 1990;31:1298–1302.

201. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the

first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A

prospective multicenter study. N Engl J Med 1988;319:983–989.

202. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology

1981;80:800–809.

203. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of

esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986;6:318–331.

204. Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal

varices and variceal bleeding. Hepatology 1985;5:419–424.

205. Price HL, Cooperman LH, Warden JC. Control of the splanchnic circulation in man. Role of betaadrenergic receptors. Circ Res 1967;21:333–340.

206. Braillon A, Moreau R, Hadengue A, et al. Hyperkinetic circulatory syndrome in patients with

presinusoidal portal hypertension. Effect of propranolol. J Hepatol 1989;9:312–318.

207. Kiire CF. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with noncirrhotic portal fibrosis. BMJ 1989;298:1363–1365.

208. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of

gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and

prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter

Study Group. N Engl J Med 1991;324:1532–1538.

209. Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to

pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet

1995;346:1056–1059.

210. Andreani T, Poupon RE, Balkau BJ, et al. Preventive therapy of first gastrointestinal bleeding in

patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy

and placebo. Hepatology 1990;12:1413–1419.

211. Ideo G, Bellati G, Fesce E, et al. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics:

a prospective, randomized study. Hepatology 1988;8:6–9.

1540

212. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in

patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856–861.

213. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of

portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902–908.

214. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in

cirrhotic patients: a randomized multicenter trial. The PROVA Study Group. Hepatology

1991;14:1016–1024.

215. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in

patients with cirrhosis. N Engl J Med 2005; 353:2254–2261.

216. Grace ND, Muench H, Chalmers TC. The present status of shunts for portal hypertension in

cirrhosis. Gastroenterology 1966;50:684–691.

217. D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review.

Hepatology 1995;22:332–354.

218. Lo GH, Lai KH, Cheng JS, et al. Prophylactic banding ligation of high-risk esophageal varices in

patients with cirrhosis: a prospective, randomized trial. J Hepatol 1999;31:451–456.

219. Svoboda P, Kantorova I, Ochmann J, et al. A prospective randomized controlled trial of

sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. Surg Endosc

1999;13:580–584.

220. Grace ND, Groszmann RJ, Garcia-Tsao G, et al. Portal hypertension and variceal bleeding: an

AASLD single topic symposium. Hepatology 1998;28:868–880.

221. Castaneda B, Morales J, Lionetti R, et al. Effects of blood volume restitution following a portal

hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 2001;33:821–825.

222. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus

workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167–

176.